title: Quality standards, safety and efficacy of blood-derived serum eye drops: A review.
abstract: Serum eye drops (SEDs) are being used increasingly to treat dry eye syndrome and persistent corneal epithelial defects, and are usually prescribed when conventional treatments fail. SEDs are commonly sourced from the patient's own blood via an autologous collection. Although SEDs are clearly beneficial, they are not available for those patients that cannot donate sufficient blood, and some centres are moving to allogeneic SEDs. Many studies have reported that both allogeneic and autologous SEDs are effective. However, few large randomised controlled trials have been conducted to date, and clinical evidence is therefore limited to smaller studies. Alternatives to serum are also being explored, such as platelet lysate and products made from platelet rich plasma, as they are a rich source of growth factors. This article reviews how some centres are approaching allogeneic collections for SEDs, and alternatives to serum that are currently being explored.
authors: Sanquin Blood Supply, Department of Product and Process Development, Amsterdam, The Netherlands.
authors: Pieter F
authors: PF
authors: van der Meer
authors: International Consultancy in Blood Components Quality/Safety Improvements, Audit/Inspection and DDR Strategies, London, UK. Electronic address: jseghatchian@btopenworld.com.
authors: Jerard
authors: J
authors: Seghatchian
authors: The Australian Red Cross Blood Service, Sydney, Australia.
authors: Denese C
authors: DC
authors: Marks
mesh_terms: D001771:Blood Banks; D002986:Clinical Trials as Topic; D006801:Humans; D009883:Ophthalmic Solutions / Q000009:adverse effects* / Q000592:standards*; D012449:Safety; D044967:Serum / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D009883:Ophthalmic Solutions
keywords: Efficacy of SED; Quality standard of SED safety; Serum eye drops